Physician profile
Robert Stuart Bridge
NPI 1336374909
$2,255.75
in general payments reported to CMS, 2019-2025
20 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $56.89 · 2021: $231 · 2022: $357 · 2023: $300 · 2024: $537 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,452 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.00 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $626.63 | 2019-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $498.59 | 2019-2025 | Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $246.84 | 2020-2024 | Entyvio |
| Madrigal Pharmaceuticals | $137.58 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $96.43 | 2024-2025 | Zenpep, Vowst |
| Genzyme Corporation | $95.22 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.11 | 2020-2025 | Relistor, Trulance |
| Regeneron Healthcare Solutions, INC. | $73.21 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $69.29 | 2025 | Vegzelma |
| Pfizer INC. | $64.20 | 2024-2025 | |
| Ardelyx, INC. | $50.66 | 2024-2025 | Ibsrela |
| Acclarent, INC | $48.83 | 2019 | |
| Merck Sharp & Dohme LLC | $38.53 | 2021-2023 | Dificid |
| Organon LLC | $36.14 | 2022 | |
| Capsovision, INC. | $28.08 | 2025 | Capsocam Plus |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19.07 | 2025 | Voquezna |
| Qol Medical, LLC | $14.69 | 2023 | Sucraid |
| Gilead Sciences, INC. | $11.93 | 2019 | |
| Intercept Pharmaceuticals, INC. | $11.72 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,973.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.